GlassScriptPhysician profile
Tara K Gregory
NPI 1407973993
$66,995.07
in general payments reported to CMS, 2019-2025
41 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $11K · 2021: $66.53 · 2022: $2,090 · 2023: $688 · 2024: $1,754 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,165 · Education: $98.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,671.25 |
| Food and Beverage | $2,165.24 |
| Education | $98.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20,963.26 | 2019-2025 | Livtencity, Iclusig |
| Amgen INC. | $18,061.41 | 2019-2023 | Blincyto |
| Celgene Corporation | $9,960.43 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Janssen Biotech, INC. | $5,897.16 | 2019-2025 | Talvey, Darzalex, Carvykti |
| Janssen Scientific Affairs, LLC | $5,606.25 | 2025 | |
| Janssen Global Services, LLC | $4,200.00 | 2025 | Carvykti |
| Abbvie INC. | $443.33 | 2019-2025 | |
| Astellas Pharma US INC | $228.20 | 2019-2025 | Xospata, Cresemba |
| Pharmacyclics LLC, An Abbvie Company | $203.52 | 2019-2023 | Imbruvica, Epkinly |
| Sanofi-Aventis U.S. LLC | $154.01 | 2019-2025 | |
| Beone Medicines USA, INC. | $152.41 | 2025 | Brukinsa |
| Genentech USA, INC. | $123.30 | 2019-2024 | Lunsumio, Venclexta |
| Legend Biotech USA INC. | $97.54 | 2022-2024 | Carvykti |
| Sobi, INC | $94.16 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $66.43 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $65.67 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $51.65 | 2019-2022 | |
| Daiichi Sankyo INC. | $47.12 | 2024-2025 | Vanflyta |
| Genmab U.S., INC. | $46.66 | 2023-2024 | Epkinly |
| Genzyme Corporation | $46.55 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $43.23 | 2019-2025 | Tazverik |
| Apellis Pharmaceuticals, INC. | $40.25 | 2022-2023 | Empaveli |
| Kite Pharma, INC. | $37.08 | 2025 | Yescarta |
| Incyte Corporation | $36.34 | 2021-2023 | Jakafi |
| Glaxosmithkline, LLC. | $33.08 | 2025 | Ojjaara |
| Blueprint Medicines Corporation | $28.45 | 2023 | |
| Taiho Oncology, INC. | $27.82 | 2022-2023 | |
| Pfizer INC. | $27.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $26.60 | 2019 | |
| Kyowa Kirin, INC. | $26.20 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.50 | 2019 | |
| Beigene USA, INC. | $23.26 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $22.77 | 2019 | |
| Karyopharm Therapeutics INC. | $22.16 | 2025 | Xpovio |
| Verastem, INC. | $21.07 | 2019 | |
| Terumo Bct, INC. | $16.29 | 2019 | |
| Pharmaessentia USA Corporation | $15.00 | 2022 | |
| Agios Pharmaceuticals, INC. | $14.84 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.